These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19151906)

  • 61. Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease.
    Potki SG; Anand R; Hartman R; Veach J; Grossberg G
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 May; 26(4):713-20. PubMed ID: 12188104
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of the online computerized cognitive training program BEYNEX on the cognitive tests of individuals with subjective cognitive impairment and Alzheimer’s disease on rivastigmine therapy.
    Çinar N; Şahiner TAH
    Turk J Med Sci; 2020 Feb; 50(1):231-238. PubMed ID: 31887854
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Rivastigmine in patients with Alzheimer's disease and concurrent hypertension.
    Erkinjuntti T; Skoog I; Lane R; Andrews C
    Int J Clin Pract; 2002 Dec; 56(10):791-6. PubMed ID: 12510954
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
    Kadir A; Darreh-Shori T; Almkvist O; Wall A; Långström B; Nordberg A
    Psychopharmacology (Berl); 2007 May; 191(4):1005-14. PubMed ID: 17310387
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease.
    Finkel SI
    Clin Ther; 2004 Jul; 26(7):980-90. PubMed ID: 15336465
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Safety/Tolerability and efficacy of rivastigmine in taiwanese patients with Alzheimer's disease: a prospective post-marketing surveillance study.
    Chiu PY; Dai DE; Hsu HP; Lee C; Lin JJ; Kuo HC; Huang YC; Liu YC; Tsai CP
    Clin Drug Investig; 2009; 29(11):729-38. PubMed ID: 19813776
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A pilot study evaluating the efficacy and safety of rivastigmine in patients with mixed dementia.
    Potkin SG; Alva G; Gunay I; Koumaras B; Chen M; Mirski D
    Drugs Aging; 2006; 23(3):241-9. PubMed ID: 16608379
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
    Robert P
    Curr Med Res Opin; 2002; 18(3):156-71. PubMed ID: 12094826
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
    Battle CE; Abdul-Rahim AH; Shenkin SD; Hewitt J; Quinn TJ
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013306. PubMed ID: 33704781
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Sixteen-Week Interventional Study to Evaluate the Clinical Effects and Safety of Rivastigmine Capsules in Chinese Patients with Alzheimer's Disease.
    Jia J; Ji Y; Feng T; Ye Q; Peng D; Kuang W; Ning Y; Liang Z; Fan D; Wei W; Li Y; Xiao S
    J Alzheimers Dis; 2019; 72(4):1313-1322. PubMed ID: 31744005
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.
    Visser PJ; Scheltens P; Pelgrim E; Verhey FR;
    Dement Geriatr Cogn Disord; 2005; 19(2-3):126-33. PubMed ID: 15627759
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer's disease.
    Richter N; Beckers N; Onur OA; Dietlein M; Tittgemeyer M; Kracht L; Neumaier B; Fink GR; Kukolja J
    Brain; 2018 Mar; 141(3):903-915. PubMed ID: 29309600
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers.
    Farlow M; Lane R; Kudaravalli S; He Y
    Pharmacogenomics J; 2004; 4(5):332-5. PubMed ID: 15289797
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
    Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
    Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
    Erkinjuntti T; Skoog I; Lane R; Andrews C
    Int J Clin Pract; 2003 Nov; 57(9):756-60. PubMed ID: 14686563
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.
    Gauthier S; Juby A; Morelli L; Rehel B; Schecter R;
    Curr Med Res Opin; 2006 Nov; 22(11):2251-65. PubMed ID: 17076986
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Rivastigmine effects on EEG spectra and three-dimensional LORETA functional imaging in Alzheimer's disease.
    Gianotti LR; Künig G; Faber PL; Lehmann D; Pascual-Marqui RD; Kochi K; Schreiter-Gasser U
    Psychopharmacology (Berl); 2008 Jun; 198(3):323-32. PubMed ID: 18446328
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Predictors of long-term treatment effect of rivastigmine in Alzheimer's disease: a role for beta-amyloid plasma levels?
    Sobów T; Kłoszewska I; Flirski M; Liberski P
    Neurol Neurochir Pol; 2009; 43(6):507-16. PubMed ID: 20054753
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer's disease.
    Muhlack S; Przuntek H; Müller T
    Pharmacopsychiatry; 2006 Jan; 39(1):16-9. PubMed ID: 16453249
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years.
    Farlow MR; Lilly ML;
    BMC Geriatr; 2005 Jan; 5():3. PubMed ID: 15659242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.